Compare Neurocrine Biosciences Inc (NBIX) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Toronto-Dominion Bank — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Toronto-Dominion Bank trades at $114.14 (market cap $185.79B). The key difference: Toronto-Dominion Bank is far larger — about 12.9× Neurocrine Biosciences Inc's market cap, and Toronto-Dominion Bank pays a 2.84% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Toronto-Dominion Bank for 84 Days on average.
| NBIX | TD | |
|---|---|---|
Market Cap | $14.36B | $185.79B |
Volume | 1,237,180 | 3,263,867 |
Sector | Health | Financials |
52-Week High | $185.50 | $124.80 |
52-Week Low | $123.10 | $78.32 |
Typical Hold Time | 23 Days | 84 Days |
Enterprise Value | $14.37B | $559.06B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
TD stock trades at $113.87, down 3.65% on the day, with technical indicators showing bearish momentum. The company reported strong earnings beats in recent quarters with Q2 2026 EPS of $1.98 beating expectations of $1.74. Revenue growth continues with 2025 revenue reaching $61.28B, though cash flow volatility remains a concern with operating cash flow turning negative in 2025. The $10 billion share buyback program and $108 billion Canadian infrastructure commitment signal management confidence.
TD presents a mixed investment case with solid fundamentals offset by technical weakness. The stock offers value with a reasonable P/E of 17.36 and strong analyst support (52.94% buy ratings), but faces headwinds from cash flow volatility and declining profit margins. The current price near support levels may offer entry points for long-term investors attracted to the dividend yield and buyback program.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
